Sitagliptin Phosphate Patent Expiration
Sitagliptin Phosphate is Used for managing glycemic control in adults with type 2 diabetes mellitus, often in combination with other medications like metformin or insulin. It was first introduced by Merck Sharp And Dohme Corp
Sitagliptin Phosphate Patents
Given below is the list of patents protecting Sitagliptin Phosphate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Januvia | US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr 24, 2017
(Expired) | Merck Sharp Dohme |
| Januvia | US6699871 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul 26, 2022
(Expired) | Merck Sharp Dohme |
| Januvia |
US6699871 (Pediatric) | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan 26, 2023
(Expired) | Merck Sharp Dohme |
| Januvia | US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Merck Sharp Dohme |
| Januvia | US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Merck Sharp Dohme |
| Januvia | US7125873 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul 26, 2022
(Expired) | Merck Sharp Dohme |
| Januvia |
US7125873 (Pediatric) | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan 26, 2023
(Expired) | Merck Sharp Dohme |
| Januvia | US7326708 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | Nov 24, 2026 | Merck Sharp Dohme |
| Januvia |
US7326708 (Pediatric) | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | May 24, 2027 | Merck Sharp Dohme |
| Januvia | US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Merck Sharp Dohme |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳